Short™ AE-IGF-1 is a recombinant protein of human insulin-like growth factor-I (IGF-1) that has been engineered with an N-terminal Ala-Glu sequence, enabling higher specific activity versus IGF-1 over a longer time course in small to large-scale culture systems and bioreactors. It is approximately 100-fold more biologically potent, in-vitro, than insulin and significantly increases recombinant protein production while reducing apoptosis. Short™ AE-IGF-1 is produced and tested under ISO 9001, ISO 14001, ISO 45001 accreditation, fully defined animal-free components. It is liquid stable, high purity with requisite performance at a compelling price.

• Higher effective concentration throughout the fermentation by reducing the binding of IGF-1 binding proteins present in cell culture
• Increases refolding efficiency
• Facilitates high-yield expression and recovery of the target protein
• Significantly reduces the cost of upstream manufacturing processes
• ShortTM AE-IGF-1 has no requirement for reconstitution, carrier proteins, excipients, stabilisers or aliquoting to smaller volumes
• Eliminating the need for bulk powder mixing or risk of influencing cell culture pH and osmolality
• Reduction in handling and therefore variability
• 4-year, liquid stable, shelf life at 2 to 8 °C
• ISO 45001, ISO 9001, ISO 14001 compliant production using a fully defined animal-free component process
• Two-year forecast demand maintained in secure storage

Short™ AE-IGF-1 is manufactured by CellRx using a proprietary Escherichia coli-based expression system. The process utilizes fully defined animal-free components, proprietary feed and induction methods within a high cell density (HCD), fed-batch, bioreactor system. The recombinant IGF molecule accumulates as inclusion bodies which are subsequently recovered, solubilised and refolded into a stable tertiary structure and purified using various downstream unit operations, yielding ≥95% RP-HPLC and ≥97% SDS-PAGE pure molecule that is highly bioactive. Each batch is supplied with a detailed certificate of analysis (CoA) and BSE/TSE free compliancy statement.